Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in first-degree relatives of subjects with polycystic ovary syndrome

References

• Frank S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Homburg R. What is polycystic ovarian syndrome?. Hum Reprod 2003; 17: 2495–2499
   Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165–169
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001; 7: 405–410
   PubMed Web of Science ®Google Scholar
• Deeb S S, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J A. Pro12Ala substitution in PPARγ2 is associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284–287
   PubMed Web of Science ®Google Scholar
• Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B. PPARγ2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000; 32: 413–416
   PubMed Web of Science ®Google Scholar
• Altshuler D, Hirschhorn J N, Klannemark M, Lindgren C M, Vohl M C, Nemesh J, Lane C R, Schaffner S F, Bolk S, Brewer C, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76–80
   PubMed Web of Science ®Google Scholar
• Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb S, Auwerx J, Uusitupa M, Laakso M. Two polymorphisms in the peroxisome proliferator-activated receptor-gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999; 84: 3708–3712
   PubMed Web of Science ®Google Scholar
• Beamer B, Yen C J, Andersen R, Muller D, Elahi D, Cheslin L. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806–1808
   PubMed Web of Science ®Google Scholar
• Mancini F, Vaccaro O, Sabatino L, Tufano A, Rivellese A, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999; 48: 1466–1468
   PubMed Web of Science ®Google Scholar
• Hara M, Alcoser S Y, Qaadır A, Beiswenger K K, Cox N J, Ehrman D A. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARγ gene. J Clin Endocrinol Metab 2002; 87: 772–775
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sana V, Savastano S, Zullo F, Colao A, Lombardi G. Exon 6 and 2 peroxisome proliferator-activated receptor-γ polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 887–892
   Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, Savastano S, Zullo F, Colao A, Vettor R, et al. Lack of an association between peroxisome proliferator-activated receptor-γ gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5110–5115
   PubMed Web of Science ®Google Scholar
• Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, Tapanaien J S, Laakso M. Polymorphisms in the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome. Hum Reprod 2003; 18: 540–543
   PubMed Web of Science ®Google Scholar
• San Millian J L, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale H F. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004; 89: 2640–2646
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1447
   PubMed Web of Science ®Google Scholar
• Genuth S, Alberti K G, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler W C, Lebovitz H, Lernmark A, , The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167
   PubMed Web of Science ®Google Scholar
• Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Miller S A, Dykes D D, Polesky H F. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
   PubMed Web of Science ®Google Scholar
• Legro R S, Driscoll D, Strauss J F, III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998; 95: 14956–14960
   PubMed Web of Science ®Google Scholar
• Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Aziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75: 53–58
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Kazsa K, Aziz R, Legro R S, Ghazzi M N, PCOS/Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 66–71
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos J L, Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002; 45: 959–964
   PubMed Web of Science ®Google Scholar
• Yıldız B O, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2031–2036
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book C B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801–810
   PubMed Web of Science ®Google Scholar
• Kelestimur F, Cetin M, Pasaoglu H, Coksevim B, Cetinkaya F, Unluhizarci K, Unal S, Koker A H. The prevalence and identification of risk factors for type 2 diabetes mellitus and impaired glucose tolerance in Kayseri, central Anatolia, Turkey. Acta Diabetol 1999; 36: 85–91
   PubMedGoogle Scholar
• American Diabetes Association. Screening for diabetes. Diabetes Care 2002; 25: 21–24
   Google Scholar